

Robert C Gallo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4214240/publications.pdf>

Version: 2024-02-01

166
papers

23,740
citations

15504

65
h-index

7950

149
g-index

178
all docs

178
docs citations

178
times ranked

11894
citing authors

#	ARTICLE	IF	CITATIONS
1	Complete nucleotide sequence of the AIDS virus, HTLV-III. <i>Nature</i> , 1985, 313, 277-284.	27.8	2,554
2	Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture. <i>Nature</i> , 1977, 270, 347-349.	27.8	2,063
3	HTLV-III infection in brains of children and adults with AIDS encephalopathy. <i>Science</i> , 1985, 227, 177-182.	12.6	955
4	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. <i>Nature</i> , 1990, 345, 84-86.	27.8	921
5	Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. <i>Journal of Translational Medicine</i> , 2020, 18, 179.	4.4	784
6	Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with SÃ©zary T-cell leukaemia. <i>Nature</i> , 1981, 294, 268-271.	27.8	758
7	The trans-activator gene of HTLV-III is essential for virus replication. <i>Nature</i> , 1986, 320, 367-371.	27.8	702
8	Human T-lymphotropic retroviruses. <i>Nature</i> , 1985, 317, 395-403.	27.8	683
9	onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. <i>Nature</i> , 1982, 299, 61-63.	27.8	654
10	Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. <i>Nature</i> , 1994, 371, 674-680.	27.8	592
11	The human type-C retrovirus, HTLV, in blacks from the Caribbean region, and relationship to adult T-cell leukemia/lymphoma. <i>International Journal of Cancer</i> , 1982, 30, 257-264.	5.1	578
12	The V3 domain of the HIVâ€™1 gp120 envelope glycoprotein is critical for chemokineâ€™mediated blockade of infection. <i>Nature Medicine</i> , 1996, 2, 1244-1247.	30.7	524
13	Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. <i>Nature</i> , 1982, 295, 116-119.	27.8	514
14	HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. <i>Nature</i> , 1985, 316, 72-74.	27.8	477
15	A molecular clone of HTLV-III with biological activity. <i>Nature</i> , 1985, 316, 262-265.	27.8	391
16	Multiple sclerosis and human T-cell lymphotropic retroviruses. <i>Nature</i> , 1985, 318, 154-160.	27.8	368
17	Extracellular vesicles and viruses: Are they close relatives?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9155-9161.	7.1	368
18	Molecular cloning and characterization of the HTLV-III virus associated with AIDS. <i>Nature</i> , 1984, 312, 166-169.	27.8	360

#	ARTICLE	IF	CITATIONS
19	Productive dual infection of human CD4+ T lymphocytes by HIV-1 and HHV-6. Nature, 1989, 337, 370-373.	27.8	354
20	Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology, 1981, 112, 355-360.	2.4	324
21	Nucleotide sequence of cloned cDNA of human c-myc oncogene. Nature, 1983, 303, 725-728.	27.8	324
22	Biologically diverse molecular variants within a single HIV-1 isolate. Nature, 1988, 334, 444-447.	27.8	309
23	RNA Dependent DNA Polymerase of Human Acute Leukaemic Cells. Nature, 1970, 228, 927-929.	27.8	289
24	Induction of CD4 and susceptibility to HIV-1 infection in human CD8+ T lymphocytes by human herpesvirus 6. Nature, 1991, 349, 533-535.	27.8	280
25	Expression of the HTLV-III envelope gene by a recombinant vaccinia virus. Nature, 1986, 320, 535-537.	27.8	260
26	Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature, 1995, 375, 64-68.	27.8	220
27	A survey of human leukaemias for sequences of a human retrovirus. Nature, 1983, 302, 626-628.	27.8	214
28	The Discovery of HIV as the Cause of AIDS. New England Journal of Medicine, 2003, 349, 2283-2285.	27.0	214
29	RNA of RNA Tumour Viruses contains Poly A. Nature: New Biology, 1972, 236, 227-231.	4.5	195
30	Risk of human immunodeficiency virus (HIV-1) infection among laboratory workers. Science, 1988, 239, 68-71.	12.6	190
31	Transformation of NIH 3T3 cells by a human c-sis cDNA clone. Nature, 1984, 308, 464-467.	27.8	186
32	Reverse Transcriptase Activity of Human Acute Leukaemic Cells: Purification of the Enzyme, Response to AMV 70S RNA, and Characterization of the DNA Product. Nature: New Biology, 1972, 240, 67-72.	4.5	173
33	A human onc gene homologous to the transforming gene (v-sis) of simian sarcoma virus. Nature, 1981, 292, 31-35.	27.8	171
34	Chromosomal sublocalization of human c-myc and c-fes cellular onc genes. Nature, 1983, 304, 169-171.	27.8	171
35	Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Medicine, 1997, 3, 651-658.	30.7	161
36	Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature, 1988, 334, 706-708.	27.8	158

#	ARTICLE	IF	CITATIONS
37	Utilization of human hematopoietic cell lines for the propagation and characterization of HBLV (human herpesvirus 6). <i>International Journal of Cancer</i> , 1988, 42, 787-791.	5.1	154
38	Cytokines and Growth Factors in the Pathogenesis of AIDS-Associated Kaposi's Sarcoma. <i>Immunological Reviews</i> , 1992, 127, 147-155.	6.0	148
39	Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 14807-14812.	7.1	147
40	Immunological Relationship of DNA Polymerase from Human Acute Leukaemia Cells and Primate and Mouse Leukaemia Virus Reverse Transcriptase. <i>Nature</i> , 1973, 244, 206-209.	27.8	145
41	Purification, Characterization, and Comparison of the DNA Polymerases from Two Primate RNA Tumor Viruses. <i>Journal of Virology</i> , 1973, 12, 431-439.	3.4	142
42	Hydrocortisone and some other hormones enhance the expression of HTLV-III. <i>International Journal of Cancer</i> , 1986, 37, 67-72.	5.1	127
43	Infection and transformation of fresh human umbilical cord blood cells by multiple sources of human T-cell leukemia-lymphoma virus (HTLV). <i>International Journal of Cancer</i> , 1983, 31, 413-420.	5.1	124
44	Infective transmission and characterisation of a C-type virus released by cultured human myeloid leukaemia cells. <i>Nature</i> , 1975, 256, 551-555.	27.8	122
45	History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. <i>Oncogene</i> , 2005, 24, 5926-5930.	5.9	118
46	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E992-9.	7.1	117
47	Reducing the global burden of HTLV-1 infection: An agenda for research and action. <i>Antiviral Research</i> , 2017, 137, 41-48.	4.1	116
48	Isolation of HTLV-transformed B-lymphocyte clone from a patient with HTLV-associated adult T-cell leukaemia. <i>Nature</i> , 1984, 310, 505-506.	27.8	115
49	Association of human T-cell leukaemia/lymphoma virus with the Tac antigen marker for the human T-cell growth factor receptor. <i>Nature</i> , 1983, 305, 733-736.	27.8	101
50	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. <i>Nature</i> , 1987, 328, 548-550.	27.8	101
51	Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. <i>Nature Medicine</i> , 1995, 1, 667-673.	30.7	99
52	Time to eradicate HTLV-1: an open letter to WHO. <i>Lancet</i> , The, 2018, 391, 1893-1894.	13.7	97
53	Can existing live vaccines prevent COVID-19?. <i>Science</i> , 2020, 368, 1187-1188.	12.6	92
54	Antibody persistence and T-cell balance: Two key factors confronting HIV vaccine development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15614-15621.	7.1	88

#	ARTICLE	IF	CITATIONS
55	Natural antibodies to human T-cell leukemia/lymphoma virus in healthy venezuelan populations. International Journal of Cancer, 1984, 34, 501-506.	5.1	83
56	Geographic distribution of HTLV-I and identification of a new high-risk population. International Journal of Cancer, 1988, 42, 7-12.	5.1	83
57	Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 9412-9417.	7.1	79
58	Transformation of different phenotypic types of human bone marrow T-lymphocytes by htlv-1. International Journal of Cancer, 1984, 33, 13-17.	5.1	77
59	Seroepidemiologic Studies Of Human T-cell leukemia/lymphoma virus type I in Jamaica. International Journal of Cancer, 1985, 36, 37-41.	5.1	77
60	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17477-17482.	7.1	77
61	Reverse Transcriptase, RNA Tumour Virus Transformation and Derivatives of Rifamycin SV. Nature: New Biology, 1972, 236, 163-166.	4.5	75
62	Complete amino acid sequence of human T-cell leukemia virus structural protein p15. FEBS Letters, 1983, 162, 390-395.	2.8	75
63	Human Herpesvirus 7 (HHV-7) Strain J1: Independent Confirmation of HHV-7. Journal of Infectious Diseases, 1992, 166, 690-691.	4.0	74
64	HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Medicine, 1995, 1, 321-329.	30.7	74
65	Emerging of a SARS-CoV-2 viral strain with a deletion in nsp1. Journal of Translational Medicine, 2020, 18, 329.	4.4	71
66	A reflection on HIV/AIDS research after 25 years. Retrovirology, 2006, 3, 72.	2.0	70
67	Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	69
68	Molecular Biology of Terminal Transferas. Critical Reviews in Biochemistry, 1986, 21, 27-52.	7.5	65
69	Proviral sequences of baboon endogenous type C RNA virus in DNA of human leukaemic tissues. Nature, 1976, 262, 190-195.	27.8	64
70	Molecular cloning and analysis of a new variant of human T-cell leukemia virus (HTLV-Ib) from an African patient with adult T-cell leukemia-lymphoma. International Journal of Cancer, 1984, 34, 613-618.	5.1	64
71	Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 20476-20481.	7.1	64
72	The Exceptional Oncogenicity of HTLV-1. Frontiers in Microbiology, 2017, 8, 1425.	3.5	62

#	ARTICLE	IF	CITATIONS
73	HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 9972-9977.	7.1	60
74	40 years of the human T-cell leukemia virus: past, present, and future. F1000Research, 2019, 8, 228.	1.6	60
75	Effects of a urinary factor from women in early pregnancy on HIV-1, SIV and associated disease. Nature Medicine, 1998, 4, 428-434.	30.7	58
76	Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14331-14336.	7.1	58
77	Human retroviruses after 20 years: a perspective from the past and prospects for their future control. Immunological Reviews, 2002, 185, 236-265.	6.0	56
78	Characterization of cytopathic factors through genome-wide analysis of the Zika viral proteins in fission yeast. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E376-E385.	7.1	56
79	Anti-inflammatory effects of H2S during acute bacterial infection: a review. Journal of Translational Medicine, 2017, 15, 100.	4.4	55
80	STLV-I antibodies in feral populations of East African vervet monkeys (<i>Cercopithecus aethiops</i>). International Journal of Cancer, 1986, 38, 523-529.	5.1	54
81	The v-sis transforming gene of simian sarcoma virus is a new onc gene of primate origin. Nature, 1981, 294, 273-275.	27.8	51
82	The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet, The, 2005, 366, 1894-1898.	13.7	48
83	Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12005-E12014.	7.1	47
84	Covid-19: Time for a paradigm change. Reviews in Medical Virology, 2020, 30, e2134.	8.3	47
85	Persistent in vitro infection by human T-cell leukemia-lymphoma virus (HTLV) of normal human T-lymphocytes from blood relatives of patients with HTLV-associated mature T-cell neoplasms. International Journal of Cancer, 1983, 31, 171-180.	5.1	44
86	Surface antibodies of human myelogenous leukaemia leukocytes reactive with specific type-C viral reverse transcriptases. Nature, 1978, 276, 230-236.	27.8	42
87	Screening transplant donors for HTLV-1 and -2. Blood, 2016, 128, 3029-3031.	1.4	41
88	Selective Toxicity of Rifamycin Derivatives for Leukaemic Human Leucocytes. Nature: New Biology, 1972, 236, 166-171.	4.5	40
89	CD4 Promoter Transactivation by Human Herpesvirus 6. Journal of Virology, 1998, 72, 8797-8805.	3.4	40
90	Transfer RNA's in human leukemia. Journal of Cellular Physiology, 1969, 74, 149-153.	4.1	39

#	ARTICLE	IF	CITATIONS
91	Research and discovery of the first human cancer virus, HTLV-1. Best Practice and Research in Clinical Haematology, 2011, 24, 559-565.	1.7	38
92	Relationship between HTLV-III Neutralizing Antibody and Clinical Status of Pediatric Acquired Immunodeficiency Syndrome (AIDS) and AIDS-Related Complex Cases. Pediatric Research, 1987, 21, 547-550.	2.3	36
93	Human retroviruses in the second decade: A personal perspective. Nature Medicine, 1995, 1, 753-759.	30.7	34
94	HIV infection and pathogenesis: what about chemokines?. Journal of Clinical Immunology, 1999, 19, 293-299.	3.8	34
95	Rapamycin Reduces CCR5 Density Levels on CD4 T Cells, and This Effect Results in Potentiation of Enfuvirtide (T-20) against R5 Strains of Human Immunodeficiency Virus Type 1 In Vitro. Antimicrobial Agents and Chemotherapy, 2007, 51, 2489-2496.	3.2	33
96	Chemokine Receptors and Chemokines in HIV Infection. Journal of Clinical Immunology, 1998, 18, 243-255.	3.8	31
97	Inverse correlation between average monthly high temperatures and COVID-19-related death rates in different geographical areas. Journal of Translational Medicine, 2020, 18, 251.	4.4	29
98	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. Journal of Clinical Investigation, 2019, 129, 1314-1328.	8.2	28
99	Human T-cell growth factor: Parameters for production. Journal of Supramolecular Structure, 1980, 13, 229-241.	2.3	27
100	Antigenic characterization of a new gibbon ape leukemia virus isolate: Seroepidemiologic assessment of an outbreak of gibbon leukemia. International Journal of Cancer, 1978, 22, 715-720.	5.1	26
101	Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13168-13173.	7.1	26
102	Viruses and Bacteria Associated with Cancer: An Overview. Viruses, 2021, 13, 1039.	3.3	26
103	Antibodies against human T-cell leukemia/lymphoma virus (HTLV) and expression of HTLV p19 antigen in relatives of a T-cell leukemia patient originating from Surinam. International Journal of Cancer, 1983, 32, 337-342.	5.1	25
104	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. Nature, 1983, 303, 253-256.	27.8	24
105	Chromatographic Analyses of Isoaccepting tRNAs from Avian Myeloblastosis Virus. Journal of Virology, 1973, 12, 449-457.	3.4	24
106	Microenvironment tailors nTreg structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6298-6307.	7.1	22
107	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. Virology, 2014, 471-473, 81-92.	2.4	21
108	Shock and kill with caution. Science, 2016, 354, 177-178.	12.6	21

#	ARTICLE	IF	CITATIONS
109	Role of Mycoplasma Chaperone DnaK in Cellular Transformation. International Journal of Molecular Sciences, 2020, 21, 1311.	4.1	21
110	Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia lymphoma: a retraction. Nature, 1983, 305, 340-340.	27.8	20
111	Charles S. Mott Prize. Human T-cell leukemia (lymphotropic) retroviruses and their causative role in T-cell malignancies and acquired immune deficiency syndrome. Cancer, 1985, 55, 2317-2323.	4.1	20
112	Molecular and immunologic analysis of a chronic lymphocytic leukemia case with antibodies against human T-cell leukemia virus. Cancer, 1985, 56, 495-499.	4.1	19
113	Sequence analysis of original HIV-1. Nature, 1991, 349, 745-746.	27.8	18
114	Occurrence of HTLV antibodies in Danish patients with cutaneous T-cell lymphoma. Scandinavian Journal of Haematology, 1985, 34, 455-462.	0.0	18
115	COVID-19 Infection Among Women in Iran Exposed vs Unexposed to Children Who Received Attenuated Poliovirus Used in Oral Polio Vaccine. JAMA Network Open, 2021, 4, e2135044.	5.9	18
116	Location of human T-cell leukemia virus (HTLV) p19 antigen on virus-producing cells. International Journal of Cancer, 1984, 33, 161-165.	5.1	17
117	Seroepidemiology of human T-lymphotropic retrovirus type I (HTLV-I) in residents of niigata prefecture, Japan. Comparative studies by indirect immunofluorescence microscopy and enzyme-linked immunosorbent assay. International Journal of Cancer, 1985, 35, 301-306.	5.1	17
118	Use of oral polio vaccine and the incidence of COVID-19 in the world. PLoS ONE, 2022, 17, e0265562.	2.5	17
119	The evidence for involvement of type C RNA tumor viruses in human acute leukemia. Cancer, 1974, 34, 1398-1405.	4.1	16
120	Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4453-E4462.	7.1	16
121	Asparaginyl-tRNA and Resistance of Murine Leukaemias to L-Asparaginase. Nature, 1970, 227, 1134-1136.	27.8	15
122	Antibodies against three purified structural proteins of the human type-C retrovirus, HTLV, in Japanese adult T-cell leukemia patients, healthy family members, and unrelated normals. International Journal of Cancer, 1983, 32, 583-590.	5.1	15
123	Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17. Pathogens and Disease, 2015, 73, ftv062.	2.0	14
124	Origins of human T-lymphotropic viruses. Nature, 1986, 320, 219-219.	27.8	13
125	First isolation of HTLV-III. Nature, 1986, 321, 119-119.	27.8	13
126	Patterns of conserved gp120 epitope presentation on attached HIV-1 virions. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9893-E9902.	7.1	12

#	ARTICLE	IF	CITATIONS
127	Time to Go Back to the Original Name. <i>Frontiers in Microbiology</i> , 2017, 8, 1800.	3.5	12
128	Tampering of Viruses and Bacteria with Host DNA Repair: Implications for Cellular Transformation. <i>Cancers</i> , 2021, 13, 241.	3.7	10
129	Antibody to human T cell leukaemia virus type III in Australian homosexual men with lymphadenopathy. <i>Medical Journal of Australia</i> , 1984, 141, 274-276.	1.7	10
130	Retroviruses in human leukemia. <i>Hematological Oncology</i> , 1983, 1, 193-204.	1.7	8
131	Placenta-bound immunoglobulins. <i>Arthritis and Rheumatism</i> , 1979, 22, 1308-1313.	6.7	7
132	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. <i>Vaccine Journal</i> , 2016, 23, 618-627.	3.1	7
133	Reply to: Lack of evidence for involvement of known human retroviruses in multiple sclerosis. <i>Nature</i> , 1986, 322, 178-178.	27.8	6
134	Kaposi's sarcoma in pregnant women. <i>Nature</i> , 1995, 377, 22-22.	27.8	6
135	HIV/AIDS Research for the Future. <i>Cell Host and Microbe</i> , 2020, 27, 499-501.	11.0	6
136	Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines. <i>Journal of Translational Medicine</i> , 2021, 19, 60.	4.4	6
137	Analysis of DnaK Expression from a Strain of <i>Mycoplasma fermentans</i> in Infected HCT116 Human Colon Carcinoma Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3885.	4.1	6
138	Human retroviruses: Cancer and aids. <i>International Journal of Cancer</i> , 1989, 44, 2-5.	5.1	5
139	Proliferative Tâ€Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings. <i>Journal of Medical Primatology</i> , 1989, 18, 363-369.	0.6	5
140	Kaposi's sarcoma and AIDS. <i>Nature</i> , 1990, 346, 801-802.	27.8	4
141	Gallo's virus sequence. <i>Nature</i> , 1991, 351, 358-358.	27.8	4
142	Developing a Successful HIV Vaccine. <i>Journal of Infectious Diseases</i> , 2015, 212, S40-S41.	4.0	4
143	Proteome analysis of <i>Mycoplasma fermentans</i> cultured under aerobic and anaerobic conditions. <i>Translational Medicine Communications</i> , 2019, 4, .	1.4	4
144	Evolution toward beta common chain receptor usage links the matrix proteins of HIV-1 and its ancestors to human erythropoietin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2021366118.	7.1	4

#	ARTICLE	IF	CITATIONS
145	Human Retroviruses: HTLV-I, II, and III and Their Association with Leukemia and AIDS. Annals of the New York Academy of Sciences, 1987, 511, 350-369.	3.8	3
146	A perspective on human herpes virus 6 (HHV-6). Journal of Clinical Virology, 2006, 37, S3.	3.1	3
147	Modulating the durability of anti-HIV gp120 antibody responses after vaccination: a comment on Wilson & Karp (2015). Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20150199.	4.0	3
148	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. Vaccine, 2021, 39, 3879-3891.	3.8	3
149	... and his response. Nature, 1991, 351, 358-358.	27.8	2
150	Reply to "Anti-KS activity still a mystery". Nature Medicine, 1998, 4, 748-748.	30.7	2
151	HIV-1: A Look Back from 20 Years. DNA and Cell Biology, 2004, 23, 191-192.	1.9	2
152	Letter to the Editor. Risk Analysis, 2021, 41, 387-388.	2.7	2
153	Some reflections on HIV/AIDS research after 40 years. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L1057-L1058.	2.9	2
154	Infection of the Central Nervous System by Human Retroviruses. Annals of the New York Academy of Sciences, 1994, 724, 125-132.	3.8	1
155	A historical personal perspective on human retroviruses and their infection of T cells. Transfusion, 2015, 55, 1-9.	1.6	1
156	Variability of CD4+ Cell Counts in HIV-1 Uninfected Volunteers Who Are Eligible for a Phase I HIV Vaccine Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 37-44.	2.1	1
157	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	1
158	Retroviruses in Human T-Cell Malignancies. Cancer Investigation, 1984, 2, 467-478.	1.3	0
159	Commentary remarks on "HIV/AIDS in China". Cell Research, 2005, 15, 823-823.	12.0	0
160	HIV: dark and light, then and now. Future Virology, 2006, 1, 1-3.	1.8	0
161	Human Retroviruses in the Second Decade: Some Pathogenic Mechanisms and Approaches to Their Control. , 0, , 245-269.		0
162	Kaposi's Sarcoma: Correction. Science, 1999, 283, 1115-1115.	12.6	0

#	ARTICLE	IF	CITATIONS
163	The Global Virus Network's testimony on Ebola to the U.S. Senate. F1000Research, 2014, 3, 307.	1.6	0
164	A journey with T cells, primate/human retroviruses and other persisting human T-cell tropic viruses. Reviews in Clinical and Experimental Hematology, 2003, 7, 329-35.	0.1	0
165	HIV/AIDS research after HAART. Research Initiative, Treatment Action: RITA, 2005, 11, 39-41.	0.1	0
166	Reflections on Some of the Exceptional Features of HTLV-1 and HTLV-1 Research: A Perspective. Frontiers in Immunology, 2022, 13, 859654.	4.8	0